John K. Cini - 07 Jan 2023 Form 4 Insider Report for Sonnet BioTherapeutics Holdings, Inc. (SONN)

Signature
/s/ John Harry Cross III, power of attorney
Issuer symbol
SONN
Transactions as of
07 Jan 2023
Net transactions value
$0
Form type
4
Filing time
17 Feb 2023, 15:46:16 UTC
Previous filing
22 Dec 2022
Next filing
05 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SONN Common Stock Disposed to Issuer -18,551 -46% 21,720 07 Jan 2023 Direct F1, F2, F3
transaction SONN Common Stock Award +18,551 +85% 40,271 07 Jan 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 14, 2022, the Reporting Person was granted 18,551 restricted stock units to be settled in shares of common stock, par value $0.0001. On January 7, 2023, the 18,551 restricted stock units granted to the Reporting Person were rescinded and canceled. On the same day, the Reporting Person was granted a restricted stock award of 18,551 shares of common stock. The shares in connection with the restricted stock award become fully vested on January 1, 2024, provided the Reporting Person remains in continuous service through such date.
F2 A Form 4 that was filed by the Reporting Person on December 22, 2022, incorrectly included amounts in Column 5 of Table I that did not reflect a 14:1 reverse stock split of the Issuer's common stock, effective September 16, 2022.
F3 Includes unvested restricted stock units.